Drug Trial Radar · NCT04964934
Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)
Last checked: Nov 19, 2026Latest source record: Sep 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
315
Actual
Start
Jun 30, 2021
Primary completion
Jun 30, 2025
Study completion Sep 1, 2028
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Jul 16, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 130 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is intended to show superiority of AZD9833 in combination with CDK4/6 inhibitor (palbociclib, abemaciclib or ribociclib) versus aromatase inhibitors (anastrozole or letrozole) in combination with CDK4/6 inhibitor in patients with hormone receptor-positive (HR-positive), human epidermal growth factor receptor 2-negative (HER2-negative) metastatic breast cancer with detectable ESR1 mutation.
Conditions
- ER-Positive HER2-Negative Breast Cancer
Interventions
AZD9833Drug
Dosage formulation: AZD9833 tablets will be administered orally
AZD9833 PlaceboDrug
Dosage formulation: AZD9833 placebo tablets will be administrated orally.
AnastrozoleDrug
Dosage formulation: anastrozole tablets will be administered orally.
Anastrozole placeboDrug
Dosage formulation: anastrozole placebo tablets will be administrated orally.
LetrozoleDrug
Dosage formulation: letrozole tablets will be administered orally.
Letrozole placeboDrug
Dosage formulation: letrozole placebo tablets will be administered orally.
PalbociclibDrug
Dosage formulation: palbociclib tablets/capsules will be administered orally
AbemaciclibDrug
Dosage formulation: abemaciclib tablets will be administered orally
Luteinizing hormone-releasing hormone (LHRH) agonistDrug
Men (when medically applicable) and pre- or peri-menopausal women are required to receive a monthly LHRH agonist.
RibociclibDrug
Dosage formulation: ribociclib tablets will be administered orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free survival (PFS) assessed by the Investigator as defined by response evaluation criteria in solid tumors (RECIST version 1.1)Time frame: From randomization until the earlier of the progression event or death (approximately 2 years)
Locations
264 sites in 23 countries. Site status is shown where the registry gives one.
Research Site
Phoenix, Arizona
Research Site
Hot Springs, Arkansas
Research Site
Little Rock, Arkansas
Research Site
Long Beach, California
Research Site
San Diego, California
Research Site
Santa Rosa, California
Research Site
Grand Junction, Colorado
Research Site
Lone Tree, Colorado
Research Site
Fort Myers, Florida
Research Site
Jacksonville, Florida
Research Site
Jacksonville, Florida
Research Site
St. Petersburg, Florida
Research Site
Atlanta, Georgia
Research Site
Atlanta, Georgia
Research Site
Atlanta, Georgia
Research Site
Park Ridge, Illinois
Research Site
Fort Wayne, Indiana
Research Site
Indianapolis, Indiana
Research Site
Baltimore, Maryland
Research Site
Boston, Massachusetts
Research Site
Fairhaven, Massachusetts
Research Site
Foxborough, Massachusetts
Research Site
Milford, Massachusetts
Research Site
South Weymouth, Massachusetts
Research Site
Detroit, Michigan
Research Site
Grand Rapids, Michigan
Research Site
Rochester, Minnesota
Research Site
Oxford, Mississippi
Research Site
Kansas City, Missouri
Research Site
St Louis, Missouri
Research Site
Billings, Montana
Research Site
Omaha, Nebraska
Research Site
Camden, New Jersey
Research Site
Ridgewood, New Jersey
Research Site
Brooklyn, New York
Research Site
East Syracuse, New York
Research Site
New Hyde Park, New York
Research Site
New York, New York
Research Site
New York, New York
Research Site
Shirley, New York
Showing 40 of 264 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.